There are three critical areas where companies most often go wrong: data preparation and training, choosing tools and specialists and timing and planning.

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.

The module targets Claude Code, Claude Desktop, Cursor, Microsoft Visual Studio Code (VS Code) Continue, and Windsurf. It also harvests API keys for nine large language models (LLM) providers: ...